The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy
Open accessAbstract
Induction and maintenance of cytotoxic T lymphocyte (CTL) activity specific for a primary endogenous tumor was investigated in vivo. The simian virus 40 T antigen (Tag) expressed under the control of the rat insulin promoter (RIP) induced pancreatic β-cell tumors producing insulin, causing progressive hypoglycemia. As an endogenous tumor antigen, the lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) was introduced also under the control of the RIP. No significant spontaneous CTL activation against GP was observed. However, LCMV infection induced an antitumor CTL response which efficiently reduced the tumor mass, resulting in temporarily normalized blood glucose levels and prolonged survival of double transgenic RIP(GP × Tag2) mice (137 ± 18 d) as opposed to control RIP-Tag2 mice (88 ± 8 d). Surprisingly, the tumor-specific CTL response was not sustained despite the facts that the tumor cells continued to express MHC class I and LCMV-GP–specific CTLs were present and not tolerized. Subsequent adoptive transfer of virus activated spleen cells into RIP(GP × Tag2) mice further prolonged survival (168 ± 11 d), demonstrating continued expression of the LCMV-GP tumor antigen and MHC class I. The data show that the tumor did not spontaneously induce or maintain an activated CTL response, revealing a profound lack of immunogenicity in vivo. Therefore, repetitive immunizations are necessary for prolonged antitumor immunotherapy. In addition, the data suggest that the risk for induction of chronic autoimmune diseases is limited, which may encourage immunotherapy against antigens selectively but not exclusively expressed by the tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Self-citationImmunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Ohashi, P. S., Oehen, S., Buerki, K., Pircher, H., Ohashi, C. T., Odermatt, B., Malissen, B., Zinkernagel, R. M., & Hengartner, H. (1991) · Cell · doi:10.1016/0092-8674(91)90164-t · Cited by 1,173
Self-citationTumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050
Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen
Pircher, H., Bürki, K., Lang, R., Hengartner, H., & Zinkernagel, R. M. (1989) · Nature · doi:10.1038/342559a0 · Cited by 1,019
Self-citationKawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
Cobbold, S. P., Jayasuriya, A., Nash, A., Prospero, T. D., & Waldmann, H. (1984) · Nature · doi:10.1038/312548a0 · Cited by 863
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., & Stern, P. L. (1997) · Immunology Today · doi:10.1016/s0167-5699(96)10075-x · Cited by 770
Antigenicity of Murine Skin Tumors Induced by Ultraviolet Light2
Kripke, M. L. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.5.1333 · Cited by 478
Cancer antigens: immune recognition of self and altered self.
Houghton, A. N. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.1 · Cited by 420
Lymphocytic Choriomeningitis Virus
(2016) · Molecular Detection of Human Viral Pathogens · doi:10.1201/b13590-72 · Cited by 402
Cromme, F. V., Airey, J., Heemels, M. T., Ploegh, H. L., Keating, P. J., Stern, P. L., Meijer, C. J., & Walboomers, J. M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.1.335 · Cited by 330
How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model
von Herrath, M. G., Dockter, J., & Oldstone, M. B. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90101-5 · Cited by 304
Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs
Kündig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J. L., Battegay, M., Lother, H., Gessner, A., Kühlcke, K., Ohashi, P. S., Hengartner, H., et al. (1995) · Science · doi:10.1126/science.7761853 · Cited by 301
Self-citationVitiligo in patients with metastatic melanoma: A good prognostic sign
Nordlund, J. J., Kirkwood, J. M., Forget, B. M., Milton, G., Albert, D. M., & Lerner, A. B. (1983) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(83)70182-9 · Cited by 288
Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells
Adams, T. E., Alpert, S., & Hanahan, D. (1987) · Nature · doi:10.1038/325223a0 · Cited by 265
Self-citationGenes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes
Pel, A. V., Van Der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethéa, B., Van Den Eynde, B., Uyttenhove, C., Renauld, J., & Boon, T. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00084.x · Cited by 218
Antibodies to normal human melanocytes in vitiligo.
Naughton, G. K., Eisinger, M., & Bystryn, J. C. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.1.246 · Cited by 216
The role of tyrosinase in autoimmune vitiligo
Song, Y.-H., Connor, E., Li, Y., Zorovich, B., Balducci, P., & Maclaren, N. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91709-4 · Cited by 197
Induction of anti-self-immunity to cure cancer
Nanda, N. K., & Sercarz, E. E. (1995) · Cell · doi:10.1016/0092-8674(95)90047-0 · Cited by 196
Hara, I., Takechi, Y., & Houghton, A. N. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1609 · Cited by 184
Interactions between SV40 large‐tumor antigen and the growth suppressor proteins pRB and p53
Ludlow, J. W. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344486 · Cited by 178
Boon, T., & Kellermann, O. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.1.272 · Cited by 148
Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
Huang, A. Y.-C., Bruce, A. T., Pardoll, D. M., & Levitsky, H. I. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.3.769 · Cited by 140
Lymphocytic Choriomeningitis Virus
Lehmann-Grube, F. (1971) · Springer eBooks · doi:10.1007/978-3-7091-8276-5 · Cited by 139
Tumor immunotherapy: the tumor cell as an antigen-presenting cell
Ostrand‐Rosenberg, S. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90075-2 · Cited by 130
Klavinskis, L. S., Whitton, J. L., Joly, E., & Oldstone, M. B. A. (1990) · Virology · doi:10.1016/0042-6822(90)90336-p · Cited by 128
Visseren, M. J. W., van Elsas, A., van der Voort, E. I., Ressing, M. E., Kast, W. M., Schrier, P. I., & Melief, C. J. M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.8.3991 · Cited by 121
Limited capacity for tolerization of CD4+ T cells specific for a pancreatic β cell neo-antigen
Förster, I., Hirose, R., Arbellt, J. M., Clausen, B. E., & Hanahant, D. (1995) · Immunity · doi:10.1016/1074-7613(95)90002-0 · Cited by 119
Melief, C. J. M., & Kast, W. M. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00081.x · Cited by 114
Onrust, S. V., Hartl, P. M., Rosen, S. D., & Hanahan, D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118406 · Cited by 99
Self-citationZinkernagel, R. M., Pircher, H., Ohashi, P. S., Oehen, S., Odermatt, B., Mak, T. W., Arnheiter, H., Bürki, K., & Hengartner, H. (1991) · Immunological Reviews · doi:10.1111/j.1600-065x.1991.tb00601.x · Cited by 97
Self-citationCan Co‐stimulated Tumor Immunity be Therapeutically Efficacious?
Hellströum, K. E., Hellström, I., & Chen, L. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00079.x · Cited by 76
Moskophidis, D., Assmann-Wischer, U., Simon, M. M., & Lehmann-Grube, F. (1987) · European Journal of Immunology · doi:10.1002/eji.1830170707 · Cited by 69
Direct analysis of tumor-associated peptide antigens
Slingluff, C. L., Hunt, D. F., & Engelhard, V. H. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90077-9 · Cited by 59
Cited by
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
Dube, D. H., & Bertozzi, C. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1751 · Cited by 1,598
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Metadata
- Authors
- Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R. M., & Ohashi, P. S.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1997-08-29
- Volume
- 186
- Issue
- 5
- Pages
- 645-653
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W1983467545
- Cited by
- 309
- References
- 37
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.